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Purpose: Age-related macular degeneration (AMD) is thought to be a polygenetic disease. It is divided into three subtypes;
neovascular AMD (nAMD), polypoidal choroidal vasculopathy, and retinal angiomatous proliferation (RAP). These
subtypes  are  thought  to  have  different  pathophysiological  and  genetic  backgrounds.  We  aimed  to  investigate  the
relationships between single nucleotide polymorphisms (SNPs) in candidate genes and subtypes of AMD in the Japanese
population.
Methods: We genotyped 685 AMD patients and 277 controls for four SNPs of the selected candidate genes: rs800292 in
complement factor H, rs10490924 in age-related maculopathy susceptibility 2 (ARMS2), rs2301995 in elastin (ELN), and
rs1801133 in methylenetetrahydrofolate reductase (MTHFR). Case-control studies were performed using these AMD
subtypes. Logistic regression analysis was performed using a history of hypertension, diabetes mellitus, and smoking as
cardiovascular risks.
Results: The genotype-dominant or recessive distribution of all four SNPs differed significantly between the controls and
the AMD patients. In the subtype analysis, there were significant differences between the controls and the AMD patients
in genotype distributions. This was true for all AMD subtype analyses of both rs800292 (complement factor H) and
rs10490924 (ARMS2). Logistic regression analysis indicated the TT genotype of the ARMS2 gene to be significantly more
common in RAP patients (p=1.54×10−13, odds ratio: 22.18). In contrast, there were significant differences in the genotype
distribution between the controls and nAMD patients only for rs2301995 (ELN, p=0.022) and rs1801133 (MTHFR,
p=2.50×10−3).
Conclusions: Our results indicate that SNPs of the ARMS2 gene may serve as strong genetic markers of RAP, and that
SNPs of the ELN and MTHFR genes are potential genetic markers for nAMD.
Age-related macular degeneration (AMD) is a leading
cause of blindness in Western countries, and its prevalence is
increasing  in  Japan  [1,2].  AMD  is  thought  to  be  a
heterogeneous multifactorial disease associated with several
environmental factors and genetic variants. Factors such as
hypertension [3] and cigarette smoking [4] are closely related
to  the  development  of  AMD.  Identification  of  AMD-
susceptibility genes might increase our ability to predict the
risk of developing AMD. Complement factor H (CFH) is
reportedly related to AMD in Caucasians [5]. In addition, age-
related  maculopathy  susceptibility  2  (ARMS2)  and  high-
temperature requirement factor A1 have been shown to be
associated with AMD in both Japanese and Caucasian patients
[6-10]. The CFH polymorphism Y402H has been reported to
be associated with AMD in studies conducted worldwide.
However, several Japanese studies have found Y402H to be
unrelated to AMD [11-14]. Other studies of the Japanese
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population  have  shown  an  association  between  CFH 
rs800292  and  AMD  [14-16].  Two  studies  examined  gene
polymorphisms  associated  with  retinal  angiomatous
proliferation (RAP) [17,18].
In  Japan,  exudative  AMD  includes  both  neovascular
AMD  (nAMD)  and  serous  retinal  pigment  epithelial
detachment  without  choroidal  neovascularization,  while
polypoidal choroidal vasculopathy (PCV) and RAP have been
defined as specific forms of exudative AMD [19]. Reported
frequencies of each subtype in the Japanese population are
35.3% for nAMD, 54.7% for PCV, and 4.5% for RAP [20].
PCV  occurs  in  less  than  8%  of  Caucasians  [21-24].
Histopathological  examination  of  PCV  demonstrated
choroidal vessels to be similar to those in atherosclerosis or
choroidal neovascularization [25]. As these AMD subtypes
may  have  different  pathophysiological  and  genetic
backgrounds,  we  undertook  this  study  of  the  associations
between genetic markers or mutations and individual AMD
subtypes.
Several candidate genes for atherosclerosis have been
reported.  Elastin  (ELN)  is  among  the  markers  of
atherosclerosis [26] and neovascularization [27,28]. Kondo et
al. [29] reported an ELN gene polymorphism (rs2301995) to
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2751confer  susceptibility  only  for  PCV,  not  for  nAMD.  They
reported the frequency of the rs2301995 polymorphism in the
ELN gene to differ significantly between the PCV and control
groups.
Methylenetetrahydrofolate reductase (MTHFR) is a key
enzyme in the homocysteine cycle. Hyperhomocysteinemia
reportedly is a risk for AMD [30,31] and induces vascular
endothelial growth factor in the retina of a rat model [32].
Thus,  the  MTHFR  gene  is  among  the  candidates  for
atherosclerosis susceptibility genes [33,34].
The  present  study  aimed  to  use  single-nucleotide
polymorphisms  (SNPs)  to  investigate  the  relationships
between AMD subtypes and potential susceptibility genes,
ARMS2, CFH, MTHFR, and ELN, in Japanese subjects. We
determined the frequencies of three AMD subtypes, along
with  the  age  and  gender  distributions  of  the  study’s
participants. We also analyzed four SNPs for AMD subtype
associations and calculated corresponding odds ratios (ORs).
METHODS
Subjects:  All  AMD  patients  and  control  subjects  were
recruited at Nihon University Surugadai Hospital in Tokyo
between 2001 and 2010. In total, 685 patients (478 men and
207 women; mean age 72.0±8.8 years) were diagnosed with
AMD by color fundus photography, fluorescein angiography,
and  indocyanine  green  angiography.  The  patient  group
included 253 diagnosed with nAMD, 381 with PCV, and 51
with RAP. All study subjects were asked if they had a history
of hypertension, diabetes mellitus, and/or smoking (including
both previous and current smoking at the time of the study).
In total, 277 subjects without AMD (111 men and 166 women;
mean age 72.9±8.7 years) served as control subjects. There
were no remarkable findings from the fundus examinations of
the  controls.  Smokers  were  defined  as  current  or  former
smokers, nonsmokers as subjects with no previous or current
smoking history. Informed consent was obtained from all
participants  as  per  the  protocol  approved  by  the  Human
Studies Committee of Nihon University.
Genotyping:  DNA  was  extracted  from  peripheral  blood
leukocytes by the phenol and chloroform extraction technique
[35,36]. Briefly, the samples were centrifuged for 10 min at
1,500× g, and the pellet was resuspended in 3 ml of solution
1, which consisted of 10 mM tris (pH 7.5), 10 mM KCl, 10 mM
MgCl2,  and  Nonidet  P40  (Sigma,  St.  Louis,  MO),  and
incubated on a rotator for 30 min. The tube was centrifuged
as  described  above  for  10  min,  and  the  supernatant  was
removed to another tube. Two milliliters of solution 2 (10 mM
Tris (pH 7.5), 10 mM KCl, 10 mM MgCl2, 50 mM NaCl, 5 mM
EDTA (pH 8.0), 25 ml 10% SDS) and 10.4 ml of proteinase
K (20 mg/ml H2O; Sigma) were added to the supernatant.
After incubation on a rotator at 37 °C overnight, 2.2 ml of
phenol was added and incubate on a rotator for 30 min. The
sample was centrifuged as described above for 10 min, and
the supernatant was removed with a large-bore tip to another
tube. Phenol purification was repeated twice: 2.2 ml of phenol/
chloroform/isoamyl alcohol was added, and incubation and
centrifugation  were  performed  described;  2.2  ml  of
chloroform was added and incubation and centrifugation were
performed again. The 400 ml of aqueous layer was transferred
carefully to a new 1.5-ml microcentrifuge tube to which 1 ml
of cold 100% ethanol was added, mixed, and incubated for 15
min at 20 °C. Genotyping was performed using the TaqMan
SNP Genotyping Assay (Applied Biosystems, Carlsbad, CA).
TaqMan SNP Genotyping Assays were performed using the
method for Taq amplification [37,38].
Plates were read on an SDS 7700 instrument with the end-
point  analysis  mode  of  the  SDS,  version  1.6.3,  software
package (Applied Biosystems). Genotypes were determined
visually, based on the dye-component fluorescent emission
data depicted in the X-Y scatter plot of the SDS software.
Genotypes were also automatically determined by applying
signal processing algorithms of the software [35,36].
Statistical analysis: Data are shown as means, plus or minus
standard  deviation  (±SD).  Differences  among  the  nAMD,
PCV, RAP, and control groups were assessed by the ANOVA
(ANOVA), followed by Fisher’s protected least significant
difference  (PLSD)  test.  Hardy–Weinberg  equilibrium  was
assessed by chi-square analysis. The overall distribution of the
SNP alleles was determined using 2×2 contingency tables.
The distributions of SNP genotypes in the AMD patients and
the controls were tested using a 2-sided Fisher’s exact test and
multiple logistic regression analysis. Statistical significance
was established at p<0.05. Because we examined four SNPs,
we applied multiple comparisons with a strict p value (0.05/
SNP number in this study: four, p<0.0125).
Logistic  regression  analyses  for  assessing  the
contributions of major risk factors and the independence of
each SNP in relation to AMD were performed using SPSS
software for Windows, version 12 (SPSS, Chicago, IL).
RESULTS
The clinical features of AMD patients and the control group
are shown in Table 1. There were no significant differences
in age or history of hypertension between the AMD patients
and the control group. There were significantly more males,
and the frequencies of smoking were higher in the patient
group  than  in  the  control  group.  However,  there  were
significantly  fewer  subjects  with  diabetes  mellitus  in  the
patient group than in the control group.
Genotype and allele distributions of the four SNPs are
shown in Table 2. All four SNPs in the controls were in
Hardy–Weinberg equilibrium (data not shown, p>0.05). The
genotype-dominant or recessive distribution of all four SNPs
differed significantly between the control and AMD groups.
Subtype analysis revealed a significant difference between the
controls and the AMD patients in genotype distributions for
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2752all  AMD  subtypes,  and  both  rs800292  (CFH)  and
rs10490924 (ARMS2). There were significant differences in
the  genotype  distributions  of  rs2301995  (ELN)  and
rs1801133  (MTHFR)  between  the  controls  and  nAMD
patients.
The results of logistic regression analysis, adjusted for
confounding factors, are shown in Table 3. This analysis was
performed for the dominant or recessive genotype models that
showed  significant  results,  as  presented  in  Table  2.
Susceptibility genotypes were those with high frequencies in
patient  groups  in  case-control  studies.  CFH  genotype
distributions differed significantly between the controls and
all AMD subtypes, especially for nAMD (p=7.66×10−8; OR:
2.90). Similarly, the ARMS2 genotype distributions differed
significantly between the controls and all AMD subtypes. In
particular,  the  TT  genotype  of  the  ARMS2  gene  was
significantly more frequent in RAP patients (p=1.54×10−13,
OR:  22.18).  In  contrast, SNPs  in  the  ELN (p=0.022)  and
MTHFR  (p=2.50×10−3)  genes  were  associated  only  with
nAMD, that is, not with either PCV or RAP.
Multiple logistic regression analysis was performed to
determine the independence of the four SNPs as risk factors
for AMD (Table 4). Each p value and 95% CI for the SNPs
showed a statistically significant difference after adjustment
for all confounding factors. Each SNP was confirmed to be an
independent risk factor for AMD.
DISCUSSION
Our results indicated significant differences between all AMD
subtypes and the controls in the distributions of genotypes and
alleles of SNPs in the  CFH and  ARMS2 genes. Both the
CFH SNP (rs800292) and ARMS2 SNP (rs10490924) are
located within exons and are known to be I62V and A69S
missense mutations. Although several studies have examined
the functions of these genes, controversies concerning their
exact functions persist [37,38].
As in previous reports, the SNPs of CFH (rs800292) and
ARMS2  (rs10490924)  were  both  strongly  associated  with
AMD  in  our  study.  In  comparing  these  two  genes,  the
ARMS2 SNP is a more powerful marker of AMD than is the
CFH SNP. The odds ratio (OR) for CFH was equal in the three
subtypes, suggesting that CFH might be a marker for all AMD
subtypes. In contrast, the OR for ARMS2 was markedly higher
for RAP than for the other subtypes. These results may support
the theory suggested by Hayashi et al. [18]. They reported an
SNP in the ARMS2 gene to be highly associated with all three
subtypes, with the association being strongest for RAP and
weakest for PCV. They concluded that PCV and RAP might
thus be subtypes of AMD that are genetically distinct from
nAMD. We agree with their conclusion. ARMS2 gene might
serve  as  strong  genetic  markers  of  RAP.  There  may  be
pathological distinctions among these three subtypes. The
significant  differences  between  these  two  SNPs  in  case-
control studies using AMD subtypes might be explained as
follows: 1) The CFH and ARMS2 genes may influence a
common  factor  such  aging  in  all  three  subtypes.  2)  An
unknown gene might affect each of these genotypes.
We  examined  the  histopathology  of  human  PCV
specimens excised during the diagnosis of nAMD. CD68-
positive  cells  were  detected  around  hyalinized  vessels.
Hypoxia-inducible  factor  (HIF)-1alpha  positive
inflammatory  cells  were  located  in  the  stroma  of  these
specimens.  Our  results  indicate  that  the  hyalinization  of
choroidal  vessels,  like  arteriosclerosis,  is  characteristic  of
PCV [27]. Other investigators reported that ELN is highly
associated with the calcification of elastic fibers in human
atherosclerotic plaques [26]. Therefore, the ELN gene was
considered  to  be  a  candidate  gene  for  PCV.  Because  the
rs2301995 SNP in the ELN gene was already reported to be
associated with PCV [30], we conducted association studies
for all three subtypes using this SNP. Since rs2301995 is
located in the intron, it is not clear whether this SNP affects
gene function. Although a previous study demonstrated TT
TABLE 1. CHARACTERISTICS OF STUDY PARTICIPANTS.
Parameters Total AMD
                              Case
                                                                              p-value                nAMD                    PCV                   RAP                Control
No. of subjects 685   253 381 51 277
Age (mean±SD) 72.0±8.8 0.146 73.7±7.5 69.9±9.1 80.1±6.8 72.9±8.7
Male/female 478/207                  <0.0001* 188/65 271/110 19/32 111/166
Hypertension (%) 39.1 0.254 38.3 39.4 41.2 43.0
Diabetes mellitus (%) 10.7 <0.0001* 12.6 9.4 9.8 19.5
Smoking (%) 34.7 <0.0001* 34.8 37.3 15.7 17.7
       Abbreviations:  AMD  represents  age-related  macular  degeneration,  nAMD  represents  neovascular  age  related  macular
       degeneration,  PCV  represents  polypoidal  choroidal  vasculopathy,  RAP  represents  retinal  angiomatous  proliferation,  N
       represents number, SD represents standard deviation. Information on hypertension, diabetes mellitus and smoking was obtained
       from the medical history of each patient. p-values reflect comparisons between case and control groups. p-values were calculated
       using Fisher's exact test. *p<0.05
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2755homozygosity to be a risk factor for PCV, we found CC
homozygosity  to  be  higher  in  the  nAMD  group.  These
findings suggest that the CC homozygosity of rs2301995 is
related to nAMD rather than PCV.
In addition to these results, several other reports have
demonstrated a relationship between the ELN protein and
neovascularization  [27,28].  Skeie  et  al.  [27]  reported  that
ELN abnormalities might play a role in the neovascularization
that occurs in AMD. Sivaprasad et al. [28] reported that serum
ELN-derived peptides might increase the risk of conversion
from early AMD to neovascular AMD. Taken together, these
reports  suggest  that  ELN  might  be  related  to
neovascularization. To our knowledge, ours is the first report
showing the ELN SNP (rs2301995) to be associated with
nAMD but to have no association with PCV. The previously
reported, opposite results may be due to the different sample
sizes in our study and that of Kondo et al. [29], who analyzed
only 74 cases. We believe our results to be more reliable than
theirs  because  our  sample  was  much  larger.  Since  we
investigated  only  one  SNP,  we  cannot  conclude  that  the
ELN gene has no association with PCV.
It is known that rs1801133 is a missense mutation in the
MTHFR gene, which is located in the exon known as A222V.
Although Haas et al. [39] concluded that this variant was not
related  to  AMD,  there  is  a  widely  accepted  view  that
homocysteine is a risk factor for atherosclerosis [31,33] and
AMD [30]. Therefore, we examined the association between
this  variant  and  AMD  subtypes  in  Japanese  subjects.
Significant differences were noted among the nAMD and
control groups, suggesting MTHFR to be a potential marker
of AMD. In addition, our results also indicate that nAMD
might not be related to atherosclerosis. Most previous studies
showed TT homozygosity to be more common in subjects
with atherosclerosis than in those without it. However, we
found the rate of CC homozygotes to be higher in the AMD
group  than  in  the  controls.  This  is  quite  the  opposite  of
previous reports on atherosclerosis. This variant may be a
genetic marker that does not affect gene function, and the C
or T allele may be linked to different susceptibility alleles for
either atherosclerosis or AMD.
To our knowledge, this is the first application of logistic
regression  analysis  to  confounding  factors  known  to  be
associated with AMD risk in three AMD subtypes (Table 3).
All genotypes showing significant differences in the simple
case-control study also yielded significant p values from the
logistic regression analyses. These results suggest that each
of the genotypes examined is an independent risk factor for
AMD.
The  present  study  is  the  first  to  examine  potential
correlations of the MTHFR and ELN genes with each of three
AMD subtypes based on examinations of SNPs. Our findings
suggest  that  polymorphisms  of  each  gene  are  potentially
useful genetic markers of AMD, and indicate that SNPs of the
ARMS2 gene may serve as strong genetic markers of RAP.
The major limitation of this study is that only one SNP in each
of the four genes was examined in a rather small numbers of
patients. These results are preliminary, especially for RAP.
Based  on  the  present  results,  we  plan  further  studies  to
investigate  specific  SNPs  for  each  subtype  of  AMD,
particularly those for PCV and RAP. Findings from these
studies are anticipated to facilitate clarification of the causes
of AMD.
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